SCHEMBL3318531

SCHEMBL3318531

OCCCC#Cc1ccc(-c2ccccc2)cc1.OCCCCCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 8/20 0.47
▸ FFAR4 Q5NUL3 4/20 0.47
▸ HDAC2 Q92769 2/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ MGLL Q99685 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ LTA4H P09960 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CHRNA7 P36544 1/20 0.38
▸ CHRNA10 Q9GZZ6 1/20 0.38
▸ CHRNA9 Q9UGM1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3311223 0.88 CYP1A2 (0.47) FFAR1FFAR4HDAC2HDAC1KDM4E
SCHEMBL5540196 0.83 HDAC2 (0.57) FFAR1HDAC2HDAC1MGLLALDH1A1
SCHEMBL5534575 0.83 HDAC2 (0.57) FFAR1HDAC2HDAC1MGLLALDH1A1
SCHEMBL2162241 0.81 HDAC2 (0.56) FFAR1HDAC2HDAC1MGLLLTA4H
SCHEMBL16010836 0.79 FFAR1 (0.55) FFAR1FFAR4LTA4HEPHX2TSHR
SCHEMBL2161747 0.78 CYP1A2 (0.50) FFAR1FFAR4CYP1A2CYP3A4CYP2C9
SCHEMBL23014997 0.78 CYP1A2 (0.56) FFAR1FFAR4KDM4EALDH1A1CYP1A2
SCHEMBL4948108 0.78 CYP1A2 (0.56) FFAR1FFAR4KDM4EALDH1A1CYP1A2
SCHEMBL487310 0.78 CYP1A2 (0.50) FFAR1FFAR4KDM4EALDH1A1CYP1A2
SCHEMBL2947602 0.76 CYP1A2 (0.58) FFAR1FFAR4KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550753-B2 Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2017-01-24 — — US disclosed
US-20140371266-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIV KENTUCKY RES FOUND (US) 2014-12-18 — — US disclosed
US-8846937-B2 Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-09-30 — — US disclosed
US-20100113511-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113511-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA4, CHRNA5 FFAR1 677/4885FFAR4 988/4885HDAC2 558/4885
US-20140371266-A1 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors CHRNA2, CHRNA4, CHRNA5 FFAR1 652/4885FFAR4 953/4885HDAC2 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback